Needle free diabetes care Market Trends

Needle-Free Diabetes Care Market Overview

Needle Free Diabetes Care Market Size was valued at USD 12.45 Billion in 2023. The Global Needle Free Diabetes Care industry is projected to grow from USD 13.12 Billion in 2024 to USD 23.20 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.69% during the forecast period (2024 - 2032). This is because of the growing diabetes population across the globe. People are looking for needle-free options for the intake of insulin.

Diabetes may be termed as a group of metabolic disorders, caused due to insulin deficiency. Needle-free medication is growing popular because it is a modern option to administer pain-free insulin medication to the patient. The diabetic population is multiplying around the world, which is expected to drive the needle-free diabetes care market growth.

Moreover, a large share of the population is also suffering from obesity. This has led to a rise in healthcare expenditure. The government is also rendering strong support for medication facilities, which will contribute to the growth of the market. Studies show that smoking adds to the probability of having diabetes in people. Moreover, more than 60% of the global population comprises smokers. This fact is also known to increase the risk of diabetes and may fuel the growth of the needle-free healthcare market.

Covid-19 Analysis

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The needle-less diabetes healthcare market saw a slight downfall post the pandemic, due to the lockdown and physical distancing.

However, the key companies have adopted measures to sell needle-free diabetes medication online. Moreover, people are growing aware of the need for needle-less diabetes healthcare provisions. Hence, these factors are expected to boost the growth of the needle-free diabetes care market value in the years to come.

Gennova Biopharmaceuticals, one of PharmaJet’s partners, submitted the data for its needle-free mRNA-based booster shot Omicron-specific Covid-19 for EUA to the Drug Controller General of India (DCGI) in April 2023.

NuGen Medical Devices published a study on InsuJet™, its needle-free injection device, in March 2023, stating that it yielded over 40% faster insulin uptake and significantly quicker onset of action on diabetic patients versus multiple clinical trials carried out across the Netherlands using needles.

PharmaJet was also selected by WHO for million+ polio vaccination campaigns in Pakistan in August 2022. In this endeavor, the company will administer needle-free vaccines to 2.7 million children.

NovaXS Biotech from the United States unveiled a new prototype of its smart medical device for needle-free injection therapy also in June 2022. The company’s patent-pending technology, Telosis propels a tiny stream of medicine within just 0.3 seconds without puncturing a needle while evaluating the coming injections data so that more informed decisions about the patient can be made by doctors. As the first remote medication and self-administration monitoring platform, the firm suggested that it provided an easy and painless option to deliver drugs at home. NovaXS’ first indication is IVF procedures.

Gerresheimer AG and Portal Instruments have joined forces to bring innovative needle-free drug delivery solutions to chronically ill patients, as announced in May 2022. Their aim is to make injections painless for patients together.

NovaXS Biotech has recently secured investment support for their patented needle-free injector early this year – March 2022. This device is connected via cloud with doctors who have access to information about their patients based on how much time they are being injected, how often they receive shots, how much volume should be administered at each dose, as well as what temperature medication should be maintained before taking effect.

Take, for example, Gerresheimer AG, in May 2022, increased its range of drug delivery technologies with an investment in Portal Instruments based in the United States, which is a developer of the next-generation needle-free drug delivery technology. Gerresheimer and Portal Instruments have teamed up to improve the patient experience, especially for patients suffering chronic illnesses such as those requiring injectable biologics and biosimilars. These advances into new technological areas and collaboration between market players are poised to stimulate market growth.

Needle-Free Diabetes Care Market Trends

Drivers

A few factors may drive the growth of the needle-free diabetes care market share. There have been increasing cases of diabetes and obesity in the population around the globe. These cases have contributed to the hike in healthcare expenditure for the people. Moreover, the government has been rendering strong support to the development of needle-free medication for diabetes. Hence, these factors are expected to accelerate global market growth.

Opportunities

The major companies that account for the largest needle-free diabetes care market share are adopting various trends such as new product launches in the field. The advancements in technology and research are adding to its growth. Moreover, most companies are adopting R&D market trends. Hence, these factors serve as opportunities for global market growth.

Restraints

There are a few factors that may inhibit the growth of the needle-free diabetes care market. One of the most important of them is the lack of awareness among people regarding the use of needle-free healthcare. Moreover, these needle-less diabetes care products are a bit expensive. Hence, these factors may hinder market growth.

Challenges

Some factors that may challenge the key diabetes healthcare providers include the cost of needle-free products. They are quite expensive and are not affordable to the majority of the diabetic population around the globe. These needle-free care products are also not available that easily. Hence, these factors challenge the key companies of the global market.

Cumulative Growth Analysis

The needle-free diabetes care market is anticipated to grow at a high speed in the years to come. This is because of the growing diabetes population across the globe. People are looking for needle-free options for the intake of insulin.

Value Chain Analysis

People are growing aware of needle-free diabetes healthcare products. These products are growing popular because of the numerous benefits they offer, without having to hurt your skin or body. Many key companies of the market have also adopted trends such as innovations and product launches. The government is also supporting market research and development. Hence, these factors may fuel the growth of the industry in the global needle-free diabetes care market forecast.

Needle-Free Diabetes Care Market Segmentation

The global needle-free diabetes care market is classified into many segments such as device types, treatment, application, and end-user. Listed below are the needle-less diabetes healthcare market segments:

Needle-Free Diabetes Care Market By Device Types

• 
  

  Diagnostic devices

  
  




• 
  

  Instant glucose monitoring

  
  


• 
  

  Continuous glucose monitoring

  
  




• 
  

  Treatment devices

  
  




• 
  

  Insulin pen

  
  


• 
  

  Insulin patch

  
  


• 
  

  Insulin pump

  
  


• 
  

  Insulin inhaler

  
  


• 
  

  Insulin jet injector

  
  

Needle-Free Diabetes Care Market By Treatment

• 
  

  Insulin patch

  
  


• 
  

  Inhaled insulin

  
  


• 
  

  Oral insulin

  
  


• 
  

  Others

  
  

Needle-Free Diabetes Care Market By Application

• 
  

  Insulin delivery

  
  


• 
  

  Others

  
  

Needle-Free Diabetes Care Market By End-user

• 
  

  Hospitals & clinics

  
  


• 
  

  Diagnostic centres

  
  


• 
  

  Others

  
  

Needle-Free Diabetes Care Market Regional Analysis

The regional division of the needle-free diabetes care market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. Among them, North America is expected to rule over the global market over the forecast period (2022 – 2030). This is because most of the obese and diabetic population in the globe belongs to the North American region.

Moreover, there are huge changes in the lifestyle of people to maintain their health. This region will be followed by Europe, with the second-largest share in the global needle-free diabetes care industry. However, the Asia Pacific region is anticipated to witness the fastest market growth rate over the forecast period. This is because the Asia Pacific comprises a large share of the diabetic population.

Competitive Landscape

The needle-free diabetes care industry is dominated by a few companies that play a vital role in the growth of the market. These healthcare companies are called the key companies of the market. They contribute to the largest share of the market profit.

The companies account for the market profits by adopting various needle-free diabetes care market trends such as joint ventures, product launches, company expansions, and procurements. They are innovative insulin medication options for diabetic patients.

Key Players

Below are the key companies that offer needle-free diabetes care in the global market, with the location of their headquarters:

• 
  

  Medical International Technology Inc. (US)

  
  


• 
  

  European Pharma Group (Netherland)

  
  


• 
  

  Zogenix Inc. (US)

  
  


• 
  

  Antares Pharma Inc. (US)

  
  


• 
  

  Valeritas Inc. (US)

  
  


• 
  

  3M Company (US)

  
  


• 
  

  Endo International plc. (US)

  
  


• 
  

  INJEX Pharma AG (Germany)

  
  


• 
  

  Bioject Medical Technologies Inc. (US)

  
  


• 
  

  Crossject SA (France)

  
  


• 
  

  PharmaJet (US)

  
  


• 
  

  PenJet Corporation (US)

  
  

Recent Developments 

• 
  

  Echo Therapeutics has developed a needle-free diabetic tester that uses a patch instead of a needle poke. The transdermal biosensor examines the blood analytes through the skin with blood drawn from the body.

  
  


• 
  

  DiaMonTech launched its diabetes monitor D-Base that measures blood glucose levels by passing an infrared ray through the skin. The levels are evaluated by monitoring the temperature changes on the skin.

  
  


• 
  

  Portal Instruments launched its jet-injection device that injects insulin into the skin through a ‘hair-thin’ stream.

  
  

Report Overview

This report delivers all the information about the growth of the global needle-free diabetes care market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected needle-free diabetes care market outlook by the year 2030.

Geographically

• 
  

  Europe

  
  


• 
  

  Asia-Pacific

  
  


• 
  

  North America

  
  


• 
  

  Middle East & Africa

  
  


• 
  

  Rest of the world